Related Experiment Video
Updated: Jul 17, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Mid-dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill
Jing Wang1, Yuanchen Li2, Siqi Huang3
1Department of Pharmacy, Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Abstract:
This study aimed to evaluate the association between polymyxin B (PMB) exposure and acute kidney injury (AKI) and analyze the risk factors for PMB-induced AKI in critically ill patients. Plasma concentrations of PMB were determined using an ultraperformance liquid chromatography-tandem mass spectrometer in intensive care unit patients who were administered PMB. Univariate and multivariate analyses were conducted to identify risk factors. A receiver operating characteristic curve was constructed to assess the discriminant power of the factors and to identify the cutoff value for AKI. The white blood cell count and estimated area under the concentration-time curve (AUC) of patients administered PMB were independent risk factors for PMB-induced AKI, where AUC were calculated using a first-order pharmacokinetic equation based on the mid-dosing interval concentration (C1/2t ) and peak concentration. The area under the receiver operating characteristic curve of the final model was 0.805 (95% confidence interval, 0.690-0.921). The cutoff value for the combined predictor was 0.57. Alternatively, when using C1/2t , which was strongly correlated with AUC, as the only independent risk factor, the analysis showed that the 3.47 μg/ml threshold provides favorable differentiation between the AKI and non-AKI groups. These results provide insightful information for therapeutic drug monitoring-guiding PMB dosing in clinical practice.
Insights
White blood cell count and polymyxin B (PMB) exposure, measured by area under the concentration-time curve (AUC), are key risk factors for acute kidney injury (AKI) in critically ill patients. Therapeutic drug monitoring can guide PMB dosing.
Area of Science:
- Pharmacology
- Nephrology
- Critical Care Medicine
Background:
- Polymyxin B (PMB) is crucial for treating multidrug-resistant Gram-negative infections.
- Acute kidney injury (AKI) is a significant complication associated with PMB therapy.
- Identifying risk factors for PMB-induced AKI is essential for patient safety.
Purpose of the Study:
- To investigate the association between PMB exposure and AKI in critically ill patients.
- To identify independent risk factors contributing to PMB-induced AKI.
- To establish predictive thresholds for AKI risk.
Main Methods:
- Plasma PMB concentrations were measured using ultra-performance liquid chromatography-tandem mass spectrometry.
- Univariate and multivariate analyses identified risk factors for AKI.
- Receiver operating characteristic (ROC) curve analysis determined the predictive power and cutoff values.
Main Results:
- White blood cell count and estimated area under the concentration-time curve (AUC) of PMB were independent risk factors for AKI.
- The final predictive model achieved an area under the ROC curve of 0.805.
- A C1/2t threshold of 3.47 μg/ml demonstrated favorable differentiation for AKI risk.
Conclusions:
- White blood cell count and PMB AUC are significant predictors of AKI in critically ill patients.
- Therapeutic drug monitoring of PMB, particularly C1/2t, can aid in optimizing dosing and mitigating AKI risk.
- These findings support the clinical implementation of PMB therapeutic drug monitoring to improve patient outcomes.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology

